Cirtec Medical Corporation, a strategic outsourcing partner of complex medical devices including minimally invasive and active implantable devices, today announced that it has acquired NovelCath, a vertically integrated manufacturer of highly engineered catheter delivery systems based in Brooklyn Park, MN.
“We are excited to add NovelCath’s capabilities to our portfolio,” stated Brian Highley, Cirtec CEO. “We continually look for ways to expand our manufacturing capabilities and enhance our value-added services to customers. This acquisition is a natural fit for us.”
NovelCath specializes in minimally invasive interventional delivery systems ranging from structural heart to electrophysiology and neurovascular applications. They are experienced in design collaboration, development, manufacture of highly engineered braided and coiled reinforced catheter shafts, complex steerable and multi-directional sheath designs, and microcatheters.
This acquisition further strengthens Cirtec’s structural heart business which includes design and development, vertical integration of components, and full-device-assembly for both implantable devices and complex delivery systems. The NovelCath facility located adjacent to Cirtec’s Minneapolis headquarters, will become Cirtec’s Center of Excellence for Catheters and Delivery Systems, and will include expanded Nitinol processing, catheter development, assembly, packaging, and volume manufacturing capabilities with a path to Costa Rica production.
Tim Maes, NovelCath CEO and one of four founding partners commented, “We are thrilled to be joining Cirtec Medical. This is a tremendous opportunity for our organization and employees to continue our growth trajectory by joining and contributing to the growth of a recognized leader in the medical device space.”
